Pharmacovigilance Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse events or any other drug-related problem, with the aim to improve the care and safety of patients and to contribute to the protection of public health.

Our president Diana Bracco, born in Milan, is President and CEO of the Bracco Group, a healthcare multinational and world leader in imaging diagnostics with a consolidated turnover of over 1.7 billion euros, around 3,700 employees, and a portfolio of over 2,500 patents. Founded in 1927 by Elio Bracco, the pharmaceutical company annually invests 10% of its imaging diagnostics turnover in research and development.

HSE Policy The Health, Safety, and Environment (HSE) Policy conveys the principles of the Bracco Group on health, safety, and environmental matters.

Transparency The Bracco Group is proud to collaborate with many Healthcare Professionals and Healthcare Organizations to support their activities and to disseminate scientific information.

Purpose and values Bracco has always been a company with people at its heart, which is why improving people's lives is both our Purpose and the benchmark by which we measure our success.

SonoVue Contrast-enhanced ultrasound. Bringing value to diagnostic imaging

Fulvio Renoldi Bracco Vice President of the Board and CEO Bracco Imaging. Read his CV.

MFDS (Korean Ministry of Food and Drug Safety) 브라코이미징코리아 제품목록

Anti-corruption The Global Anti-Corruption Program provides guidance on how to conduct business in a fair, ethical, and legal manner and summarizes the laws and principles to which everyone working for the Bracco Group must adhere.

Quality Policies Bracco is committed to provide safe, reliable, effective products and services for the Patients and Customers through Quality excellence. The Quality organization has the appropriate level of independence and authority to act using the highest quality standards and promoting the quality culture company-wide.